Why the study?
Does ACE-I administration increase plasma levels of the anti-fibrotic peptide Ac-SDKP in humans?
Does ACE-I administration increase plasma levels of the anti-fibrotic peptide Ac-SDKP in humans?
ACE inhibitors significantly increase plasma levels of the anti-fibrotic tetrapeptide Ac-SDKP in humans, providing a mechanistic rationale for testing their efficacy in preventing constrictive pericarditis.
No takes yet. Share an insight, caveat, or question.
ACE-I raise anti-fibrotic Ac-SDKP; supports mechanistic rationale for trials in constrictive pericarditis.
Mnguni et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: